Pharmaceutical concern Renovo (RNVO) has announced failure in its Phase II trials for its scar treatment Juvista.
The fully-listed concern reported that the treatment 'did not meet its primary or secondary endpoints' adding that the company will 'conduct further exploratory analysis' to 'determine the future of the Juvista development programme.'
Following the news CEO Mark Ferguson said he was both 'surprised' and 'disappointed' by its failure adding that the group - which has £44 million in cash will be considering 'all options open to it to maximise shareholder value'
Friday, February 11, 2011
Disaster for Renovo
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment